Pressemeldungen

Sequana Medical announces the appointment of Dr Oliver Gödje as Chief Medical Officer

Ghent, BELGIUM – 4 May 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer, with immediate effect. Dr Gödje replaces Gijs Klarenbeek, MD, who remains with Sequana...

Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 28 May 2020

PRESS RELEASE 28 April 2020 07:00 CEST REGULATED INFORMATION   Publication of Annual Report 2019 Ghent, BELGIUM – 28 April 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today invites the holders of securities...

Sequana Medical announces 2019 Full Year Results and 2020 Outlook

PRESS RELEASE 19 MARCH 2020 07:00 CET REGULATED INFORMATION   Continued strong progress in U.S. NASH-related and global heart failure programmes Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast presentation today at 14:00 CET / 09:00 ET   Ghent, BELGIUM – 19 March 2020 –...

Sequana Medical Notice of 2019 Full Year Results and 2020 Outlook

Ghent, BELGIUM – 12 March 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, will announce its results for the full year ended 31 December 2019 and outlook for 2020 on Thursday 19 March 2020. The management team will host...

Transparency Notifications from Shareholders

Regulated Information Ghent, BELGIUM – 21 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of...

Transparency Notifications from Shareholders

Regulated Information Ghent, BELGIUM – 3 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of...

Sequana Medical announces new share capital amount and new number of shares

Regulated Information Ghent, Belgium, 29 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations...

Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation

Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failure   Ghent, BELGIUM – 10 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver...

Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients

  The study aims to: Evaluate the safety of alfapump DSR in patients with heart failure Assess the feasibility of alfapump DSR to remove excess sodium and fluid from the body Explore the potential impact of DSR therapy to restore response to diuretics Ghent, BELGIUM – 7 January 2020 – Sequana Medical NV (Euronext Brussels:...

Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update

Regulated information   Continued strong progress since IPO in February 2019: Commenced POSEIDON pivotal study to support approval of the alfapump® in the U.S. & Canada Achieved clinical proof-of-concept of Direct Sodium Removal (DSR), potential breakthrough therapy for volume overload due to heart failure Conference call with live webcast presentation today at 14:00 CET /...
1 2 3 5

Abonnieren Sie unsere Pressemitteilungen

I agree to the Sequana Medical Privacy Policy

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our
Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close